Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, marking a 111% increase year-over-year. The company achieved a net income of $49.5 million, significantly up from $26.0 million in the previous quarter, and an Adjusted EBITDA of $91.1 million.
Subscriber growth was robust, with a 38% increase year-over-year, reaching 2.4 million. The company reaffirmed its full-year 2025 revenue guidance of $2.3 billion to $2.4 billion and raised its Adjusted EBITDA guidance to between $295 million and $335 million.
This post appeared first on 24/7 Wall St.